- Home
- LIQT vs EQ Comparison
LIQT vs EQ Comparison
Compare LIQT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIQT
- EQ
- Stock Information
- Founded
- LIQT 2004
- EQ 2017
- Country
- LIQT Denmark
- EQ United States
- Employees
- LIQT N/A
- EQ N/A
- Industry
- LIQT Industrial Machinery/Components
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- LIQT Technology
- EQ Health Care
- Exchange
- LIQT Nasdaq
- EQ Nasdaq
- Market Cap
- LIQT 16.1M
- EQ 13.1M
- IPO Year
- LIQT N/A
- EQ 2018
- Fundamental
- Price
- LIQT $1.90
- EQ $0.89
- Analyst Decision
- LIQT Strong Buy
- EQ Buy
- Analyst Count
- LIQT 2
- EQ 3
- Target Price
- LIQT $4.80
- EQ $3.00
- AVG Volume (30 Days)
- LIQT 15.0K
- EQ 20.3M
- Earning Date
- LIQT 08-13-2025
- EQ 08-19-2025
- Dividend Yield
- LIQT N/A
- EQ N/A
- EPS Growth
- LIQT N/A
- EQ N/A
- EPS
- LIQT N/A
- EQ N/A
- Revenue
- LIQT $14,986,815.00
- EQ $30,406,000.00
- Revenue This Year
- LIQT $36.89
- EQ N/A
- Revenue Next Year
- LIQT $16.33
- EQ N/A
- P/E Ratio
- LIQT N/A
- EQ N/A
- Revenue Growth
- LIQT N/A
- EQ N/A
- 52 Week Low
- LIQT $1.34
- EQ $0.27
- 52 Week High
- LIQT $3.20
- EQ $1.50
- Technical
- Relative Strength Index (RSI)
- LIQT 45.88
- EQ 70.41
- Support Level
- LIQT $1.94
- EQ $0.46
- Resistance Level
- LIQT $2.25
- EQ $0.80
- Average True Range (ATR)
- LIQT 0.23
- EQ 0.18
- MACD
- LIQT -0.05
- EQ 0.03
- Stochastic Oscillator
- LIQT 0.00
- EQ 52.58
About LIQT LiqTech International Inc.
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is engaged in three businesses that are diesel particulate filters (DPF) for the control of soot from diesel engines, turnkey ceramic membranes systems, and complete water treatment plants. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, and kiln furniture. Its operating segment includes Water, Ceramics, and Plastics.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.